This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00971-07v1 51/12/4382    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Critchley, I. A. Articles by Janjic, N. Search for Related Content PubMed PubMed Citation Articles by Critchley, I. A. Articles by Janjic, N.

National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study

Replidyne, Inc., Louisville, Colorado 80027,¹ Clinical Microbiology Institute, Wilsonville, Oregon 97070,² Replidyne, Inc., Milford, Connecticut 06460³

Received 26 July 2007/ Returned for modification 27 August 2007/ Accepted 24 September 2007

Surveillance studies conducted in the United States over the last decade have revealed increasing resistance among community-acquired respiratory pathogens, especially Streptococcus pneumoniae, that may limit future options for empirical therapy. The objective of this study was to assess the scope and magnitude of the problem at the national and regional levels during the 2005-2006 respiratory season (the season when community-acquired respiratory pathogens are prevalent) in the United States. Also, since faropenem is an oral penem being developed for the treatment of community-acquired respiratory tract infections, another study objective was to provide baseline data to benchmark changes in the susceptibility of U.S. respiratory pathogens to the drug in the future. The in vitro activities of faropenem and other agents were determined against 1,543 S. pneumoniae isolates, 978 Haemophilus influenzae isolates, and 489 Moraxella catarrhalis isolates collected from 104 U.S. laboratories across six geographic regions during the 2005-2006 respiratory season. Among S. pneumoniae isolates, the rates of resistance to penicillin, amoxicillin-clavulanate, and cefdinir were 16, 6.4, and 19.2%, respectively. The least effective agents were trimethoprim-sulfamethoxazole (SXT) and azithromycin, with resistance rates of 23.5 and 34%, respectively. Penicillin resistance rates for S. pneumoniae varied by region (from 8.7 to 22.5%), as did multidrug resistance rates for S. pneumoniae (from 8.8 to 24.9%). Resistance to ß-lactams, azithromycin, and SXT was higher among S. pneumoniae isolates from children than those from adults. ß-Lactamase production rates among H. influenzae and M. catarrhalis isolates were 27.4 and 91.6%, respectively. Faropenem MICs at which 90% of isolates are inhibited were 0.5 µg/ml for S. pneumoniae, 1 µg/ml for H. influenzae, and 0.5 µg/ml for M. catarrhalis, suggesting that faropenem shows promise as a treatment option for respiratory infections caused by contemporary resistant phenotypes.

Published ahead of print on 1 October 2007.

This article has been cited by other articles:

• Critchley, I. A., Jacobs, M. R., Brown, S. D., Traczewski, M. M., Tillotson, G. S., Janjic, N. (2008). Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem. Antimicrob. Agents Chemother. 52: 2639-2643 [Abstract] [Full Text]  
• El Moussaoui, R, Roede, B M, Speelman, P, Bresser, P, Prins, J M, Bossuyt, P M M (2008). Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 63: 415-422 [Abstract] [Full Text]